BSE:524661

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Welcure Drugs & Pharmaceuticals

Executive Summary

Welcure Drugs & Pharmaceuticals Limited engages in the wholesale of pharmaceutical and medical goods in India. More Details


Snowflake Analysis

Flawless balance sheet with weak fundamentals.

Share Price & News

How has Welcure Drugs & Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 524661's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0%

524661

-3.2%

IN Pharmaceuticals

-0.6%

IN Market


1 Year Return

308.0%

524661

52.6%

IN Pharmaceuticals

2.2%

IN Market

Return vs Industry: 524661 exceeded the Indian Pharmaceuticals industry which returned 53.5% over the past year.

Return vs Market: 524661 exceeded the Indian Market which returned 1.1% over the past year.


Shareholder returns

524661IndustryMarket
7 Day0%-3.2%-0.6%
30 Day0%-4.3%0.2%
90 Day140.0%13.4%6.7%
1 Year308.0%308.0%54.5%52.6%3.9%2.2%
3 Year104.0%104.0%26.9%23.4%2.6%-2.4%
5 Year4.1%4.1%-0.6%-4.1%41.3%30.8%

Price Volatility Vs. Market

How volatile is Welcure Drugs & Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Welcure Drugs & Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

1048.3x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 524661's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 524661's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 524661 is poor value based on its PE Ratio (1048.3x) compared to the IN Pharmaceuticals industry average (22.9x).

PE vs Market: 524661 is poor value based on its PE Ratio (1048.3x) compared to the Indian market (16.2x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 524661's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 524661 is overvalued based on its PB Ratio (58.5x) compared to the IN Pharmaceuticals industry average (2.2x).


Next Steps

Future Growth

How is Welcure Drugs & Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

27.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Welcure Drugs & Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Welcure Drugs & Pharmaceuticals performed over the past 5 years?

-58.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 524661 has a high level of non-cash earnings.

Growing Profit Margin: 524661's current net profit margins (2%) are lower than last year (12.7%).


Past Earnings Growth Analysis

Earnings Trend: 524661's earnings have declined by 58.5% per year over the past 5 years.

Accelerating Growth: 524661's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 524661 had negative earnings growth (-84.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (14.7%).


Return on Equity

High ROE: 524661's Return on Equity (5.6%) is considered low.


Next Steps

Financial Health

How is Welcure Drugs & Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: 524661's short term assets (₹386.0K) exceed its short term liabilities (₹51.0K).

Long Term Liabilities: 524661 has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: 524661 is debt free.

Reducing Debt: 524661 has not had any debt for past 5 years.

Debt Coverage: 524661 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 524661 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Welcure Drugs & Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 524661's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 524661's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 524661's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 524661's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 524661's dividend in 3 years as they are not forecast to pay a notable one for the Indian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

7.2yrs

Average management tenure


CEO

Sudhir Chandra (83 yo)

8.67yrs

Tenure

₹84,000

Compensation

Mr. Sudhir Chandra, B.Sc., B. Tech (Hons.), Dip. (Ing) has been the Managing Director and Director at Welcure Drugs & Pharmaceuticals Ltd. since February 1, 2012 and December 31, 2005 respectively. Mr. Cha ...


CEO Compensation Analysis

Compensation vs Market: Sudhir's total compensation ($USD1.14K) is below average for companies of similar size in the Indian market ($USD56.15K).

Compensation vs Earnings: Sudhir's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Sudhir Chandra
MD & Director8.67yrs₹84.00kno data
Murari Bhateja
CFO & Independent Director15.5yrs₹8.00kno data
Mitashi Bisaria
Company Secretary0.75yr₹2.00kno data
Dharam Jain
Founder & Non Executive Director18.17yrs₹2.12m14.12%
₹ 3.9m

7.2yrs

Average Tenure

80yo

Average Age

Experienced Management: 524661's management team is seasoned and experienced (7.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Sudhir Chandra
MD & Director8.67yrs₹84.00kno data
Murari Bhateja
CFO & Independent Director15.5yrs₹8.00kno data
Mitashi Bisaria
Company Secretary0.75yr₹2.00kno data
Dharam Jain
Founder & Non Executive Director18.17yrs₹2.12m14.12%
₹ 3.9m

15.2yrs

Average Tenure

80yo

Average Age

Experienced Board: 524661's board of directors are seasoned and experienced ( 15.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Welcure Drugs & Pharmaceuticals Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Welcure Drugs & Pharmaceuticals Limited
  • Ticker: 524661
  • Exchange: BSE
  • Founded: 1996
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹27.565m
  • Shares outstanding: 13.51m

Location

  • Welcure Drugs & Pharmaceuticals Limited
  • B-9 and 10, Laxmi Towers
  • L.S.C., Block C
  • Delhi
  • Delhi
  • 110034
  • India

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
524661BSE (Mumbai Stock Exchange)YesEquity SharesININRDec 2005

Biography

Welcure Drugs & Pharmaceuticals Limited engages in the wholesale of pharmaceutical and medical goods in India. The company was incorporated in 1996 and is based in Delhi, India.


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/19 12:55
End of Day Share Price2020/09/14 00:00
Earnings2020/09/30
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.